Last reviewed · How we verify
clobazam (Onfi)
Clobazam is a benzodiazepine that enhances inhibitory neurotransmission by potentiating GABA-A receptor activity in the central nervous system.
Clobazam is a benzodiazepine that enhances inhibitory neurotransmission by potentiating GABA-A receptor activity in the central nervous system. Used for Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, Adjunctive treatment of other seizure disorders.
At a glance
| Generic name | clobazam (Onfi) |
|---|---|
| Sponsor | St. Joseph's Hospital and Medical Center, Phoenix |
| Drug class | Benzodiazepine; anticonvulsant |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Clobazam binds to GABA-A receptors and increases the frequency of chloride channel opening, thereby enhancing the inhibitory effects of GABA. This results in reduced neuronal excitability and seizure threshold elevation. Unlike many other benzodiazepines, clobazam has a unique 1,5-benzodiazepine structure that may contribute to its selective anticonvulsant properties with potentially lower sedation.
Approved indications
- Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome
- Adjunctive treatment of other seizure disorders
Common side effects
- Somnolence
- Ataxia
- Fatigue
- Insomnia
- Irritability
- Constipation
Key clinical trials
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- GABA Pathways in Autism Spectrum Disorder (ASD) (NA)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- The Benefit and Safety of Older Generation Anti-Epileptic Drugs (AEDs) in Drug-Resistant Epilepsy Children (PHASE4)
- A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (PHASE2)
- An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (PHASE2)
- Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy (NA)
- Use of Clobazam for Epilepsy and Anxiety (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- clobazam (Onfi) CI brief — competitive landscape report
- clobazam (Onfi) updates RSS · CI watch RSS
- St. Joseph's Hospital and Medical Center, Phoenix portfolio CI